Please try another search
For the nine months ended 30 September 2020, OxfordImmunotec Global PLC revenues decreased 30% to $39.2M. Netloss before extraordinary items totaled $15M vs. income of$280K. Revenues reflect United States segment decrease of40% to $11.4M, Asia segment decrease of 24% to $22M. Netloss reflects Interest income decrease of 78% to $770K(income), Research and development - Balancing val increaseof 26% to $7.3M (expense).
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Revenue | 19.44 | 5.83 | 13.91 | 18.11 |
Gross Profit | 14.86 | 3.67 | 10.31 | 14.19 |
Operating Income | 0.28 | -9.83 | -6.58 | -1.92 |
Net Income | -0.15 | -9.69 | -6.03 | -1.62 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Total Assets | 210.5 | 206.61 | 219.08 | 235.25 |
Total Liabilities | 19.24 | 17.71 | 21.07 | 21.56 |
Total Equity | 191.26 | 188.89 | 198.01 | 213.69 |
Period Ending: | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -12.76 | -9.16 | -5.38 | -7.16 |
Cash From Investing Activities | 0.53 | 2.09 | -0.6 | -1.66 |
Cash From Financing Activities | -7.82 | -7.84 | -7.89 | -3.18 |
Net Change in Cash | -20.65 | -15.78 | -14.79 | -11.57 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review